CMG Pharmaceutical Co. Ltd (058820) - Cash Flow Conversion Efficiency
Based on the latest financial reports, CMG Pharmaceutical Co. Ltd (058820) has a cash flow conversion efficiency ratio of -0.020x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (₩-4.08 Billion ≈ $-2.77 Million USD) by net assets (₩201.55 Billion ≈ $136.59 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see 058820 company net worth for the company's overall valuation and market capitalisation.
CMG Pharmaceutical Co. Ltd - Cash Flow Conversion Efficiency Trend (2014–2025)
This chart illustrates how CMG Pharmaceutical Co. Ltd's cash flow conversion efficiency has evolved over time, based on yearly financial data.
CMG Pharmaceutical Co. Ltd Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of CMG Pharmaceutical Co. Ltd ranked by their cash flow conversion efficiency. Explore 058820 cash flow quality index to measure how well operating cash flow supports reported net income.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
IX Acquisition Corp.
NASDAQ:IXAQF
|
-0.071x |
|
Flanigans Enterprises Inc
NYSE MKT:BDL
|
0.062x |
|
York Timber Holdings Ltd
JSE:YRK
|
0.024x |
|
Skillsoft Corp.
NYSE:SKIL
|
-0.397x |
|
China Bicycle Co Holdings Ltd
SHE:200017
|
-0.043x |
|
Natura City Developments Tbk PT
JK:CITY
|
-0.007x |
|
HLB Global Co Ltd
KO:003580
|
-0.045x |
|
Chain Chon Industrial Co Ltd
TWO:5014
|
-0.015x |
Annual Cash Flow Conversion Efficiency for CMG Pharmaceutical Co. Ltd (2014–2025)
The table below shows the annual cash flow conversion efficiency of CMG Pharmaceutical Co. Ltd from 2014 to 2025. View 058820 stock price for real-time trading data and today's change.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | ₩201.55 Billion ≈ $136.59 Million |
₩-11.02 Billion ≈ $-7.47 Million |
-0.055x | -3672.48% |
| 2024-12-31 | ₩189.54 Billion ≈ $128.45 Million |
₩290.09 Million ≈ $196.59K |
0.002x | -92.55% |
| 2023-12-31 | ₩190.23 Billion ≈ $128.92 Million |
₩3.91 Billion ≈ $2.65 Million |
0.021x | -23.03% |
| 2022-12-31 | ₩184.95 Billion ≈ $125.34 Million |
₩4.94 Billion ≈ $3.35 Million |
0.027x | -12.40% |
| 2021-12-31 | ₩184.70 Billion ≈ $125.17 Million |
₩5.63 Billion ≈ $3.81 Million |
0.030x | +87.47% |
| 2020-12-31 | ₩181.13 Billion ≈ $122.75 Million |
₩2.94 Billion ≈ $2.00 Million |
0.016x | +3.72% |
| 2019-12-31 | ₩180.16 Billion ≈ $122.09 Million |
₩2.82 Billion ≈ $1.91 Million |
0.016x | +83.76% |
| 2018-12-31 | ₩103.98 Billion ≈ $70.47 Million |
₩886.78 Million ≈ $600.96K |
0.009x | -57.12% |
| 2017-12-31 | ₩97.94 Billion ≈ $66.38 Million |
₩1.95 Billion ≈ $1.32 Million |
0.020x | -12.90% |
| 2016-12-31 | ₩101.11 Billion ≈ $68.52 Million |
₩2.31 Billion ≈ $1.56 Million |
0.023x | -55.67% |
| 2015-12-31 | ₩46.81 Billion ≈ $31.72 Million |
₩2.41 Billion ≈ $1.63 Million |
0.052x | +248.22% |
| 2014-12-31 | ₩49.00 Billion ≈ $33.21 Million |
₩724.89 Million ≈ $491.25K |
0.015x | -- |
About CMG Pharmaceutical Co. Ltd
CMG Pharmaceutical Co., Ltd., a pharmaceutical company, develops and sells oral thin film (OTF) pharmaceuticals in South Korea. It offers Tadalafil OTF products for erectile dysfunction; Entecavir OTF products to treat hepatitis type B; Aripiprazole OTF products for schizophrenia; and Montelukast OTF products to treat asthma and allergic rhinitis. CMG Pharmaceutical Co. Ltd. has a strategic colla… Read more